Although day surgery has a good patient satisfaction and safety profile, accurate episode-of-care costs (EOCC) calculation for of this procedure compared to standard same-day admission (SDA), while considering functional outcomes, is not well known. This study assesses the EOCC for patients with a THA while comparing DS and Same Day Admission (SDA) (with a 1-day hospitalization) pathways. The episode-of-care cost (EOCC) of 50 consecutive day surgery and SDA patients who underwent a THA was evaluated. The episode-of-care cost was determined using a bottom-up Time Driven- Activity Based Funding method. Functional outcomes were measured using preoperative and postoperative Harris Hip Score (HHS). Overall, the SDA THA cost 11% more than a DS THA. The mean total EOCC of DS THA was 9 672 CAD compared to 10 911 CAD in the SDA THA group. Both groups showed an improvement in HHS score following the procedure but patients in the DS group had a significantly higher postoperative HHS score and a significantly greater improvement in their HHS score postoperatively. Day surgery THA is cost-effective, safe and associated with high patient satisfaction due to functional improvement. Providing policymakers the information to develop optimal financing methods is paramount for clinicians wishing to develop modern protocols, increase productivity while providing the optimal care for patients.
To systematically review the outcomes and complications of cosmetic stature lengthening. PubMed and Embase were searched on 10 November 2019 by three reviewers independently, and all relevant studies in English published up to that date were considered based on predetermined inclusion/exclusion criteria. The search was done using “cosmetic lengthening” and “stature lengthening” as key terms. The Preferred Reporting Item for Systematic Reviews and Meta-Analyses statement was used to screen the articles.Aims
Methods
Metal-on-metal (MoM) articulations in total hip replacement (THR) have become an attractive option for young, active patients. Short-term reports have demonstrated elevated systemic metal ion levels in the blood and urine. Disseminated concentrations of cobalt and chromium have raised concern regarding cellular toxicity, chromosomal damage and adverse local soft tissue reactions. Long-term studies are required to support the increased use of MoM bearings in younger patients given their potential deleterious effects. The purpose of the current study was to report the seven to 13 year clinical, radiographic, and metal ion results in patients following MoM THR. We prospectively followed 165 patients (196 hips) after second-generation MoM THR between July 1997 and November 2003. Functional outcome was measured using the Harris Hip Score (HHS) and the University of California Los Angeles (UCLA) Activity Score. Radiographic analysis was performed using Einzel-Bild-Roentgen-Analyse (EBRA) by two of the authors blinded to the study. Cobalt and chromium metal ions were measured from whole blood and analyzed using inductively coupled plasma-mass spectrometry as previously described.Purpose
Method
Metal-on-metal (MoM) articulations in total hip replacement (THR) have become an attractive option for young, active patients. Short-term reports have demonstrated elevated systemic metal ion levels in the blood and urine. Disseminated concentrations of cobalt and chromium have raised concern regarding cellular toxicity, chromosomal damage and adverse local soft tissue reactions. Long-term studies are required to support the increased use of MoM bearings in younger patients given their potential deleterious effects. The purpose of the current study was to report the 7–13 year clinical, radiographic, and metal ion results in patients following MoM THR. We prospectively followed 165 patients (196 hips) after second-generation MoM THR between July 1997 and November 2003. Functional outcome was measured using the Harris Hip Score (HHS) and the University of California Los Angeles (UCLA) Activity Score. Radiographic analysis was performed using Einzel-Bild-Roentgen-Analyse (EBRA) by two of the authors blinded to the study. Cobalt and chromium metal ions were measured from whole blood and analyzed using inductively coupled plasma-mass spectrometry.Introduction
Methods
The percentage of adolescents and young adults with sarcoma enrolled in multicenter clinical trials is reportedly much lower than that of younger children. We intended to determine if this remained true despite the availability of a study open to patients up to the age of 40 years Review of interim recruitment and randomization rates in a large randomized multinational trial for resectable osteosarcoma, EURAMOS-1, jointly performed by COG, COSS, EOI, and SSG, within ECT-EUROCORES. Randomization scheduled after preoperative chemotherapy and definitive surgery of the primary tumour.Aim
Method
The European and American Osteosarcoma study group (EURAMOS) was formed by four multinational study groups (COG, COSS, EOI, SSG) based upon a common understanding that broad international collaboration facilitating randomised trials was important for further progress in the field of osteosarcoma. Representatives from each group reached quick agreement on a study design; to determine whether altering post-operative therapy based on response to pre-operative chemotherapy improves outcome. Additionally, a quality-of-life sub-study was included in the project. After a three-year process to resolve regulatory and organisational issues the study opened for accrual in April 2005. Important for an efficient conduction of the trial a common infrastructure was established with central sponsorship (Medical Research Council, UK), one coordinating data centre (MRC Clinical Trials Unit, UK) and a common Safety Desk and a coordinating Quality-of-life data centre (Münster, DE). As of Dec 2008, a total of 1268 patients from 290 institution in 15 countries have been registered into the trial (AUS 16 patients; B 27; CAN 54; CH 26; D 266; DK 12; FIN 3; H 14; NL 61; NOR 23; NZ 8; OST 7; SWE 25; UK 174; USA 552) and 937 patients participate in the quality-of-life evaluation. 697 patients have been randomized and 53% are assessed as good histological responders. Due to a lower than expected randomisation rate and a higher than expected number of patients with a good histological response the accrual time will be extended by one year to summer 2010. In conclusion, EURAMOS-1 may serve as a model for a successful non-commercial multinational clinical trial in times of increasing economic and regulatory pressure. It is the fastest accruing and largest osteosarcoma trial ever. In addition, to addressing important questions in a randomised setting a common language in osteosarcoma has been established. Supported by the European Science Foundation (ESF) under the EUROCORES Program European Clinical Trials (ECT), through contract No. ERASCT-2003-980409 of the European Commission, DG Research, FP6